Related Experiment Video
Updated: Apr 27, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
17.0K
The approval process for biosimilar erythropoiesis-stimulating agents.
1Department of Medicine, Division of Nephrology, Indiana University Health, Indianapolis, Indiana jaywish@earthlink.net.
Summary
Biosimilar drugs offer significant cost savings and increased accessibility compared to reference biologics. Regulatory pathways, like the Biologics Price Competition and Innovation Act, aim for efficient approval while ensuring safety and efficacy.
Area of Science:
- Pharmaceutical Science
- Regulatory Science
- Health Economics
Background:
- Biosimilar drugs are highly similar to reference biologic products, with no clinically meaningful differences in safety, purity, or potency.
- The development of biosimilars is driven by the potential for significant cost savings and improved patient access to biologic therapies.
- The US enacted the Biologics Price Competition and Innovation Act (BPCIA) in 2009 to establish an abbreviated regulatory pathway for biosimilar approval.
Purpose of the Study:
- To define biosimilar drugs and outline the regulatory framework for their approval in the United States.
- To discuss the advantages of biosimilars, including cost reduction and enhanced accessibility.
- To examine the European Union's experience with biosimilars and its implications for the US market.
Main Methods:
- The study reviews existing definitions of biosimilar drugs as per the Public Health Service Act.
- It analyzes the legislative framework, specifically the Biologics Price Competition and Innovation Act (BPCIA).
- It references data from the European Union's approval process for biosimilar epoetin agents.
Main Results:
- The BPCIA allows for biosimilar approval based on structural and functional similarity, with clinical study requirements tailored to the degree of biosimilarity.
- Two biosimilar epoetin agents have been approved in the EU, demonstrating similar efficacy and safety to the reference product.
- Potential immunogenicity concerns, similar to those with reference biologics, may persist for biosimilars.
Conclusions:
- The BPCIA aims to streamline the efficient market entry of biosimilars while maintaining public safety.
- The uptake of biosimilars in the US will depend on balancing cost benefits against safety considerations.
- Market competition from biosimilars is expected to reduce the cost of the reference biologic agent.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
01:16Bioequivalence: Overview
2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
01:13Bioequivalence studies: Biowaivers
430
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
430
01:26FDA Approved Drugs: Changes to Approved Drugs
341
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
341
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
300
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
300
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230